NVGN Key Stats
- Novogen Files Suite of Patents for Anti-Tropomyosin Drug Technology PR Newswire Nov 26
- Novogen (NVGN) Unit Reports Strong Trilexium Data on Ovarian Cancer Street Insider Nov 25
- Wal-Mart’s Soft Quarter, Rio Tinto’s Arizona Mine Project, and 3 More Hot Stocks Wall St. Cheat Sheet Nov 14
- Novogen (NVGN) Stock Opens Higher Following Positive Findings Street Insider Nov 14
- Novogen Launches Joint Venture Aimed At Developing Drugs to Fight Ovarian Cancer PR Newswire Nov 6
- Tesla Motors and Qualcomm Benefit from Respective Upgrades, and 3 More Hot Stocks Wall St. Cheat Sheet Oct 15
- Novogen Is Poised To Soar As A Major Partnership Announcement Is Imminent Seeking Alpha Oct 15
- Novogen (NVGN) Sees Sharp Upside Move Street Insider Aug 7
- Novogen (NVGN) trading paused for volatility Street Insider Aug 7
- 4 Healthcare Stock Stories Making Midweek Headlines Jul 3
NVGN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Novogen is up 31.77% over the last year vs S&P 500 Total Return up 28.99%, ntercept Pharmaceuticals up 107.6%, and Boiron up 107.3%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Balance Sheet View Statement
Pro Ratings for NVGN
Pro Strategies Featuring NVGN
Did Novogen make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Novogen Ltd., is engaged in pharmaceutical drug development. It develops single drug capable of killing both the dominant differentiated cells in a cancer as well as the undifferentiated cancer stem cells at a therapeutic dose.